Zinc moves the needle on blood sugar in type 2 diabetes

Zinc is involved in glucose handling, and whether supplementing it can improve cardio-metabolic health in people with type 2 diabetes has been debated for years, with individual trials pointing in different directions. Type 2 diabetes management turns on markers such as HbA1c, fasting glucose, lipids and blood pressure, so any inexpensive supplement that moves them reliably would matter. Earlier work had not established whether the effects are real, let alone how they scale with dose. This dose-response meta-analysis set out to summarise the randomised evidence and formally grade its certainty.

The researchers searched PubMed, Scopus and Web of Science from inception to April 2023 for randomised controlled trials comparing oral zinc supplementation with placebo in adults with type 2 diabetes, excluding co-supplementation studies and trials in children or pregnant women. Twenty-two studies with 1442 participants were included. Glycaemic indices, lipid profiles, blood pressure, anthropometric measures, CRP, creatinine and serum zinc were extracted; certainty of evidence was assessed using GRADE methods, and a random-effects dose-response analysis was performed.

Zinc significantly improved glycaemic control: two-hour postprandial glucose fell by 34.34 mg/dl, fasting blood sugar by 23.32 mg/dl and HbA1c by 0.47. Lipids moved favourably too — LDL down 10.76 mg/dl, triglycerides down 18.23 mg/dl, total cholesterol down 12.74 mg/dl, VLDL down 5.39 mg/dl and HDL up 4.04 mg/dl. Systolic blood pressure fell 3.64 mmHg, CRP dropped 3.37 mg/l and serum zinc rose 15.38 µg/dl. Body weight, however, increased by 1.00 kg. Linear dose associations were seen per additional 10 mg/d for several markers, and the certainty of evidence was rated moderate to high.

The role of zinc in type 2 diabetes had remained genuinely controversial; this analysis, with its GRADE assessment and dose-response modelling, is a substantial step towards resolving it in zinc's favour. The moderate-to-high certainty rating and the absence of substantial publication bias on Egger's test strengthen the case beyond earlier, smaller syntheses. Still, the authors are explicit that open questions remain: the optimal form, dosage and duration of supplementation are not established, and the small weight-gain signal warrants attention in future trials.

For readers with type 2 diabetes, this is among the stronger supplement findings in the pooled literature: consistent improvements across blood sugar, lipids, blood pressure and inflammation, rated with moderate-to-high certainty. It is informational rather than a prescription — the underlying trials varied, the ideal dose and form are unknown, and decisions about diabetes care belong with a clinician. The 1.00 kg average weight increase is a genuine trade-off to weigh in the balance. Broadly, it is a reason to see zinc status as relevant to metabolic health rather than a niche concern.